Ambivalent role of FasL in murine acute graft-versus-host-disease

J Leukoc Biol. 2023 Sep 1;114(3):205-211. doi: 10.1093/jleuko/qiad040.

Abstract

Fas ligand is increased in several immune-mediated diseases, including acute graft-versus-host disease, a donor cell-mediated disorder post-hematopoietic stem cell transplantation. In this disease, Fas ligand is involved in T-cell-mediated damage to host tissues. However, the role of its expression on donor non-T cells has, so far, never been addressed. Using a well-established CD4- and CD8-mediated graft-versus-host disease murine model, we found that precocious gut damage and mice mortality are increased with a graft of donor T- and B-depleted bone marrow cells devoid of Fas ligand as compared with their wild-type counterparts. Interestingly, serum levels of both soluble Fas ligand and IL-18 are drastically reduced in the recipients of Fas ligand-deficient grafts, indicating that soluble Fas ligand stems from donor bone marrow-derived cells. In addition, the correlation between the concentrations of these 2 cytokines suggests that IL-18 production arises through a soluble Fas ligand-driven mechanism. These data highlight the importance of Fas ligand-dependent production in IL-18 production and in mitigating acute graft-versus-host disease. Overall, our data reveal the functional duality of Fas ligand according to its source.

Keywords: IL-18; allogeneic hematopoietic stem cell transplantation; gut damage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Marrow Transplantation
  • Fas Ligand Protein
  • Graft vs Host Disease*
  • Hematopoietic Stem Cell Transplantation*
  • Interleukin-18
  • Mice
  • Transplantation, Homologous

Substances

  • Fas Ligand Protein
  • Interleukin-18